Annual CFF
$218.75 M
+$101.18 M+86.06%
December 31, 2023
Summary
- As of February 12, 2025, TVTX annual cash flow from financing activities is $218.75 million, with the most recent change of +$101.18 million (+86.06%) on December 31, 2023.
- During the last 3 years, TVTX annual CFF has risen by +$91.04 million (+71.28%).
- TVTX annual CFF is now -5.65% below its all-time high of $231.86 million, reached on December 31, 2018.
Performance
TVTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$46.00 K
-$736.00 K-94.12%
September 30, 2024
Summary
- As of February 12, 2025, TVTX quarterly cash flow from financing activities is $46.00 thousand, with the most recent change of -$736.00 thousand (-94.12%) on September 30, 2024.
- Over the past year, TVTX quarterly CFF has dropped by -$78.00 thousand (-62.90%).
- TVTX quarterly CFF is now -99.98% below its all-time high of $230.96 million, reached on September 30, 2018.
Performance
TVTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$427.00 K
+$680.00 K+268.77%
September 30, 2024
Summary
- As of February 12, 2025, TVTX TTM cash flow from financing activities is $427.00 thousand, with the most recent change of +$680.00 thousand (+268.77%) on September 30, 2024.
- Over the past year, TVTX TTM CFF has dropped by -$218.32 million (-99.80%).
- TVTX TTM CFF is now -99.87% below its all-time high of $329.24 million, reached on March 31, 2021.
Performance
TVTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
TVTX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +86.1% | -62.9% | -99.8% |
| 3 y3 years | +71.3% | -91.7% | -99.6% |
| 5 y5 years | -5.7% | -91.7% | -99.6% |
TVTX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -5.6% | +86.1% | -100.0% | +107.3% | -99.8% | +268.8% |
| 5 y | 5-year | -5.6% | >+9999.0% | -100.0% | +100.8% | -99.9% | +106.3% |
| alltime | all time | -5.7% | +5783.4% | -100.0% | +100.1% | -99.9% | +101.0% |
Travere Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $46.00 K(-94.1%) | $427.00 K(-268.8%) |
| Jun 2024 | - | $782.00 K(-249.0%) | -$253.00 K(-120.6%) |
| Mar 2024 | - | -$525.00 K(-523.4%) | $1.23 M(-99.4%) |
| Dec 2023 | $218.75 M(+86.1%) | $124.00 K(-119.6%) | $218.75 M(-0.2%) |
| Sep 2023 | - | -$634.00 K(-128.0%) | $219.18 M(-1.3%) |
| Jun 2023 | - | $2.27 M(-99.0%) | $222.09 M(+0.7%) |
| Mar 2023 | - | $217.00 M(>+9900.0%) | $220.66 M(+87.7%) |
| Dec 2022 | $117.57 M(-49.3%) | $551.00 K(-75.8%) | $117.57 M(-21.7%) |
| Sep 2022 | - | $2.28 M(+174.1%) | $150.24 M(-0.1%) |
| Jun 2022 | - | $831.00 K(-99.3%) | $150.37 M(+0.4%) |
| Mar 2022 | - | $113.91 M(+243.0%) | $149.84 M(-35.3%) |
| Dec 2021 | $231.68 M(+81.4%) | $33.21 M(+1275.8%) | $231.68 M(+3.7%) |
| Sep 2021 | - | $2.41 M(+696.7%) | $223.51 M(+1.3%) |
| Jun 2021 | - | $303.00 K(-99.8%) | $220.75 M(-33.0%) |
| Mar 2021 | - | $195.75 M(+681.8%) | $329.24 M(+157.8%) |
| Dec 2020 | $127.71 M(-6248.9%) | $25.04 M(-7295.1%) | $127.71 M(+24.3%) |
| Sep 2020 | - | -$348.00 K(-100.3%) | $102.77 M(+0.4%) |
| Jun 2020 | - | $108.80 M(-1984.5%) | $102.38 M(-1619.0%) |
| Mar 2020 | - | -$5.77 M(-6176.8%) | -$6.74 M(+224.5%) |
| Dec 2019 | -$2.08 M(-100.9%) | $95.00 K(-112.9%) | -$2.08 M(+26.1%) |
| Sep 2019 | - | -$738.00 K(+127.8%) | -$1.65 M(-100.7%) |
| Jun 2019 | - | -$324.00 K(-70.8%) | $230.05 M(-1.5%) |
| Mar 2019 | - | -$1.11 M(-311.4%) | $233.46 M(+0.7%) |
| Dec 2018 | $231.86 M | $525.00 K(-99.8%) | $231.86 M(-0.4%) |
| Sep 2018 | - | $230.96 M(+7386.4%) | $232.70 M(+2970.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2018 | - | $3.08 M(-214.2%) | $7.58 M(+191.8%) |
| Mar 2018 | - | -$2.70 M(-298.5%) | $2.60 M(-52.3%) |
| Dec 2017 | $5.45 M(-241.5%) | $1.36 M(-76.7%) | $5.45 M(-667.2%) |
| Sep 2017 | - | $5.83 M(-407.6%) | -$960.00 K(-65.2%) |
| Jun 2017 | - | -$1.90 M(-1399.3%) | -$2.76 M(-0.7%) |
| Mar 2017 | - | $146.00 K(-102.9%) | -$2.78 M(-27.9%) |
| Dec 2016 | -$3.85 M(-103.8%) | -$5.04 M(-224.9%) | -$3.85 M(-258.6%) |
| Sep 2016 | - | $4.04 M(-310.6%) | $2.43 M(-105.8%) |
| Jun 2016 | - | -$1.92 M(+107.0%) | -$41.72 M(+7.8%) |
| Mar 2016 | - | -$926.00 K(-175.2%) | -$38.70 M(-138.1%) |
| Dec 2015 | $101.60 M(+6.6%) | $1.23 M(-103.1%) | $101.60 M(+1.8%) |
| Sep 2015 | - | -$40.11 M(-3726.7%) | $99.84 M(-30.4%) |
| Jun 2015 | - | $1.11 M(-99.2%) | $143.49 M(-26.8%) |
| Mar 2015 | - | $139.38 M(<-9900.0%) | $196.08 M(+105.7%) |
| Dec 2014 | $95.32 M(+228.9%) | -$533.00 K(-115.0%) | $95.32 M(-0.0%) |
| Sep 2014 | - | $3.54 M(-93.4%) | $95.32 M(-15.6%) |
| Jun 2014 | - | $53.69 M(+39.0%) | $112.91 M(+90.7%) |
| Mar 2014 | - | $38.62 M(-7382.1%) | $59.22 M(+104.3%) |
| Dec 2013 | $28.98 M(+553.1%) | -$530.30 K(-102.5%) | $28.98 M(-1.8%) |
| Sep 2013 | - | $21.13 M(>+9900.0%) | $29.51 M(+252.3%) |
| Jun 2013 | - | $0.00(-100.0%) | $8.38 M(0.0%) |
| Mar 2013 | - | $8.38 M(>+9900.0%) | $8.38 M(>+9900.0%) |
| Dec 2012 | $4.44 M | - | - |
| Aug 2010 | - | $0.00(0.0%) | $0.00(0.0%) |
| May 2010 | - | $0.00 | $0.00 |
FAQ
- What is Travere Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Travere Therapeutics?
- What is Travere Therapeutics annual CFF year-on-year change?
- What is Travere Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Travere Therapeutics?
- What is Travere Therapeutics quarterly CFF year-on-year change?
- What is Travere Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Travere Therapeutics?
- What is Travere Therapeutics TTM CFF year-on-year change?
What is Travere Therapeutics annual cash flow from financing activities?
The current annual CFF of TVTX is $218.75 M
What is the all time high annual CFF for Travere Therapeutics?
Travere Therapeutics all-time high annual cash flow from financing activities is $231.86 M
What is Travere Therapeutics annual CFF year-on-year change?
Over the past year, TVTX annual cash flow from financing activities has changed by +$101.18 M (+86.06%)
What is Travere Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of TVTX is $46.00 K
What is the all time high quarterly CFF for Travere Therapeutics?
Travere Therapeutics all-time high quarterly cash flow from financing activities is $230.96 M
What is Travere Therapeutics quarterly CFF year-on-year change?
Over the past year, TVTX quarterly cash flow from financing activities has changed by -$78.00 K (-62.90%)
What is Travere Therapeutics TTM cash flow from financing activities?
The current TTM CFF of TVTX is $427.00 K
What is the all time high TTM CFF for Travere Therapeutics?
Travere Therapeutics all-time high TTM cash flow from financing activities is $329.24 M
What is Travere Therapeutics TTM CFF year-on-year change?
Over the past year, TVTX TTM cash flow from financing activities has changed by -$218.32 M (-99.80%)